Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNYSE:BHVNNASDAQ:CERCNASDAQ:DYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.50-1.7%$13.89$7.64▼$17.75$1.61B1.762.27 million shs1.37 million shsBHVNBiohaven$15.59-0.6%$18.24$14.33▼$55.70$1.60B0.951.26 million shs4.06 million shsCERCCerecor$4.71-2.3%$2.60$1.98▼$4.50$452.20M1.441.27 million shs38,386 shsDYNDyne Therapeutics$14.46-0.8%$11.04$6.36▼$47.45$1.64B1.171.68 million shs2.50 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-1.15%+3.47%-4.59%-7.29%+76.48%BHVNBiohaven-6.75%-3.49%-23.56%-44.46%-54.29%CERCCerecor+5.70%+9.55%+18.72%-37.40%-55.86%DYNDyne Therapeutics-1.42%+8.65%+16.00%+22.64%-52.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.1021 of 5 stars3.41.00.00.02.71.70.6BHVNBiohaven3.0056 of 5 stars4.51.00.00.01.82.50.6CERCCerecorN/AN/AN/AN/AN/AN/AN/AN/ADYNDyne Therapeutics2.5458 of 5 stars4.50.00.00.01.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8039.26% UpsideBHVNBiohaven 3.07Buy$59.46281.41% UpsideCERCCerecor 0.00N/AN/AN/ADYNDyne Therapeutics 3.00Buy$44.93210.71% UpsideCurrent Analyst Ratings BreakdownLatest CERC, BHVN, DYN, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025DYNDyne TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/19/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M7.56N/AN/A$0.94 per share14.36BHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/ACERCCerecor$6.70M67.49N/AN/A$0.22 per share21.41DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%8/13/2025 (Estimated)BHVNBiohaven-$408.17M-$9.36N/AN/AN/AN/A-225.12%-158.89%8/5/2025 (Estimated)CERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ADYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)Latest CERC, BHVN, DYN, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.672.462.38BHVNBiohavenN/A2.892.89CERCCerecor0.792.192.18DYNDyne TherapeuticsN/A17.0217.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABHVNBiohaven88.78%CERCCerecor62.84%DYNDyne Therapeutics96.68%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BHVNBiohaven16.00%CERCCerecor45.70%DYNDyne Therapeutics14.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableBHVNBiohaven239102.11 million84.94 millionOptionableCERCCerecor3196.01 millionN/ANot OptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableCERC, BHVN, DYN, and ARQT HeadlinesRecent News About These CompaniesRaymond James bullish on biotech firms on favorable valuationJune 12 at 1:00 AM | in.investing.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Raymond JamesJune 11 at 10:17 AM | marketbeat.comDyne Therapeutics officer sells shares worth $1,949June 8, 2025 | investing.comMillennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)June 6, 2025 | marketbeat.comUS Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugsJune 5, 2025 | msn.comDyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research CongressJune 5, 2025 | globenewswire.comOppenheimer Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)June 4, 2025 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Earns Outperform Rating from Analysts at OppenheimerJune 2, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 56.1% in MayJune 2, 2025 | marketbeat.comSquarepoint Ops LLC Has $1.22 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)June 1, 2025 | marketbeat.comBank of America Corp DE Decreases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)June 1, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Down 5.5% - Should You Sell?May 31, 2025 | marketbeat.comEvercore ISI Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)May 30, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by BrokeragesMay 30, 2025 | marketbeat.comVoloridge Investment Management LLC Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 29, 2025 | marketbeat.comDeutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 26, 2025 | marketbeat.comWoodline Partners LP Sells 403,483 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)May 24, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by D. E. Shaw & Co. Inc.May 21, 2025 | marketbeat.com66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial MarketsMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 822,201 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)May 20, 2025 | marketbeat.comMan Group plc Has $17.59 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsSteel Dynamics Shares Climb After Tariff AnnouncementBy Dan Schmidt | June 3, 2025View Steel Dynamics Shares Climb After Tariff AnnouncementCERC, BHVN, DYN, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.50 -0.23 (-1.68%) As of 04:00 PM EasternArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Biohaven NYSE:BHVN$15.59 -0.10 (-0.64%) As of 03:58 PM EasternBiohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Cerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Dyne Therapeutics NASDAQ:DYN$14.46 -0.11 (-0.75%) As of 04:00 PM EasternDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
